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The clinical presentation of severe infection with
generalized inflammation is similar, if not identical, to
systemic inflammation induced by sterile tissue injury.
Novel models and unbiased technologies are urgently
needed for biomarker identification and disease profiling
in sepsis. Here we briefly review the article of Kamisoglu
and colleagues in this issue of Critical Care on comparing
metabolomics data from different studies to assess
whether responses elicited by endotoxin recapitulate,
at least in part, those seen in clinical sepsis.non-infectious SIRS). Metabolic profiling of plasma in
both studies was performed using non-targeted massOur inability to differentiate sepsis from non-infectious
inflammatory states has negatively impacted research
developments in diagnosis, prognosis and treatment of
sepsis. Compounding the problem, biomarker identifica-
tion and disease profiling is hampered by our reliance on a
theoretical construct that assumes disseminated infection
stimulates pattern recognition receptors, such as Toll like
receptor (TLR)4 in response to lipopolysaccharide, to
generate clinically recognizable, biochemically defined
common pathways of response in the host. The same
mediators that cause general inflammation and harm
in sepsis are required for host defence, numerous
pathways are highly redundant, and receptors that
distinguish self from non-self are also needed for the
recognition of danger signals. The result is that many
of the biomarkers used in the ICU are neither sensi-
tive nor specific enough to inform regarding specific
pathophysiologic processes.
Recent advances in ‘omic’ technologies have opened
new opportunities for sepsis research. In a recent article
published in Critical Care, Kamisoglu and colleagues [1]Correspondence: dossantosc@smh.ca
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by endotoxin recapitulate, at least in part, those seen in
clinical sepsis [2]. The study is primarily a retrospective in
silico analysis of metabolomes obtained from subjects who
participated in an experimental endotoxemia study [3]
and from patients enrolled in the Community Acquired
Pneumonia and Sepsis Outcome and Diagnostics
(CAPSOD) study who after independent audit fulfilled
criteria for sepsis and outcomes [4]. Patients in the
CAPSOD cohort were classified as uncomplicated sepsis,
severe sepsis, septic shock, and non-infected systemic
inflammatory response syndrome (‘ill’ controls with
spectrometry by the same commercial provider. In
contrast to targeted approaches that profile a small
number of known metabolites, untargeted approaches
(without restriction to particular compounds) have the
advantage of allowing for identification of metabolic
fingerprints (that is, multiple biomarkers that form a
biopattern) associated with particular endophenotypes
[5, 6]. The important insights of the study are two: the
clinical relevance of endotoxemia in sepsis, and the
applicability of metabolomics as an analytical tool in
sepsis. Because lipopolysaccharide acts through the TLR4,
endotoxin challenge is a model of TLR4 agonist-induced
SIRS [2]. The issue of the contribution of TLR signaling in
sepsis will be difficult to unravel as these receptors are
likely to be activated by both primary (pathogen-related)
and secondary (host-related) events. A discussion of the
merits and limitations of comparing high throughput
data from different studies is fundamental to the use
of genomic technologies in critical illness.
Metabolomics is heavily supported by mass spectrometry
(MS) and nuclear magnetic resonance (NMR) as parallel
technologies that provide an overview of the complete set
of small-molecule chemicals found within a biological
sample (metabolome) [4]. The main advantage of MS
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ation techniques - liquid chromatography (LC) or gas
chromatography (GC) - enhances the detection ability of
MS. The major weakness of MS is quantification. In
contrast, in NMR the peak area of a compound is directly
related to the concentration of specific nuclei, making
quantification very precise. NMR is, however, much less
sensitive. Therefore, a single analytical tool is unlikely to
detect all possible metabolites, suggesting a combination
of techniques will be required to assign metabolites
and patients to specific classes [3]. Moreover, of all
the systems biology disciplines, metabolomics is closest to
the phenotype, is profoundly affected by environmen-
tal factors, and dynamic changes suggest selection of
appropriate time points for biomarker identification
will be critical [4, 7].
In the study by Kamisoglu and colleagues biochemical
profiles obtained by GC-MS and LC-tandem MS
provided information on a total of 366 metabolites.
Since no significant differences were identified for plasma
metabolites between subgroups of sepsis survivors,
different groups were collapsed into a single group.
While loss of resolution (small number of metabolites),
and discordant time points, makes it difficult to classify
clinically relevant endophenotypes, the approach selected
by Kamisoglu and colleagues to pool ‘similar’ patients into
a single group is extensively used in systems biology to
increase the statistical power to detect differences between
groups [8, 9]. Cluster analysis, pooling metabolite groups,
also enhances the likelihood of finding clinically relevant
class-specific signatures [10, 11]. Metabolic data from
sepsis survivors and non-survivors were also pooled to
compare patients with sepsis and non-infected SIRS.
Despite individual variability, the metabolic responses
to endotoxin are similar to those seen in sepsis survivors.
The authors rationalized that similar metabolomes may
reflect TLR4 agonist-induced SIRS or common processes
of recovery. They were also able to identify specific
features that differentiate patients with SIRS from
both endotoxin and sepsis patients. While one of the
strengths of this study is the combination of clinical
data, severity assignment and metabolomics, an important
limitation is in the assumption that absence of detectable
differences indicates groups are comparable. Also, restrict-
ing the intra-study comparative analyses to metabolites
that significantly change between different conditions
maximizes the likelihood of detecting overall correlations
between studies [9].
After stratification of sepsis patients based on 28-day
survival, the direction of change of 21 of 23 metabo-
lites was the same in endotoxemia and sepsis survi-
vors (compared with non-survivors). Similar to other
studies, the metabolite group that differentiated sur-
viving versus non-surviving CAPSOD patients wasacylcarnitines [12]. In the study by Kamisoglu and
colleagues, comparison between studies was possible
because the proprietary extraction protocol used for
sample preparation was the same in both studies -
minimizing the variability associated with sample
preparation. Standard procedures consistent across
labs will be required if we want to deposit and com-
pare raw (meta)data across studies. This is the goal of
the human metabolome project, which aims to iden-
tify, quantify, and catalogue all metabolites in human
tissues and biofluids [13]. In the future, integration
networks using different types of ‘omic’ data will be
combined to allow more thorough and comprehensive
modeling of complex traits [14]. Overall, studies such
as the one conducted by Kamisoglu and colleagues
are pioneering in that they are setting the precedent for
how will we integrate, compare, analyze and generalize
results from high throughput technologies.
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